Lincoln Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2025, recommended Final Dividend of Rs. 1.80 per equity share.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.6 pts less than Nifty Microcap 250 and 9.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lincoln Pharmaceuticals' Board, at its meeting on May 22, 2025, approved audited financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion. The Board recommended a final dividend of Rs. 1.80 per equity share (18% on face value of Rs. 10), subject to shareholder approval at the upcoming AGM. For FY25, the company reported Total Income of Rs. 645.71 crore (up 5% YoY) but Net Profit declined 11.71% to Rs. 82.44 crore, with EBITDA down 7.71% to Rs. 123.97 crore and EPS at Rs. 41.11. Q4 FY25 Net Profit stood at Rs. 11.62 crore on Total Income of Rs. 161.30 crore. FII holding rose from 3.93% to 5.0% during the year, and the company has set a revenue target of Rs. 750 crore for FY26.
Despite a profit decline, the higher dividend (up from ~Rs. 1.50 paid in FY24) signals continued shareholder rewards. The mixed results — revenue growth but profit contraction — may limit upside momentum, though strong cash flows, zero debt, and FII accumulation provide some support.